Business / Finance

RSS

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).

27 Nov 2012

Hillenbrand fourth quarter net income increases 6% to $25 million

Hillenbrand revenue for the fourth quarter of 2012 grew 10% to $254 million compared to the same quarter last year. This represents 11% revenue growth on a constant currency basis.

26 Nov 2012

Viral Genetics changes name to VG Life Sciences

Viral Genetics, Inc. today announced that it has changed its name to VG Life Sciences Inc. and that it has completed its 1-for-600 reverse stock split, both of which will take effect at the open of trading on November 27, 2012.

26 Nov 2012

Renal care provider Diaverum signs contract with Bureau Veritas to standardise ISO certifications

Diaverum, one of the world's leading renal care providers, has signed a contract with Bureau Veritas (BV) to standardise ISO certifications within the company. A pilot project has successfully been rolled out in Hungary and Poland earlier this year. In 2013 the ISO certification project will be expanded to an additional five countries in Diaverum.

26 Nov 2012

Ivoclar Vivadent announces acquisition of Wieland Dental

Ivoclar Vivadent, headquartered in Schaan, Liechtenstein, announced the acquisition of Wieland Dental today. The acquisition is planned to be completed in the fourth quarter of 2012. The transaction is still subject to approval by the German Federal Cartel Office.

26 Nov 2012

Medworxx third quarter revenue increases 85.2% to $2,084,962

Medworxx Solutions Inc. announced today that it has filed with the Canadian securities authorities its Interim Consolidated Financial Statements (Unaudited), and Management's Discussion and Analysis report for the three and nine month interim periods ended September 30, 2012.

23 Nov 2012

Allon Files Preliminary Shelf Prospectus

Allon Therapeutics Inc. has filed a preliminary short form base shelf prospectus with the securities commissions in each province and territory of Canada (other than Quebec).

23 Nov 2012

Cynosure closes underwritten registered public offering of class A common stock

Cynosure, Inc., a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced the closing of its previously announced underwritten registered public offering of class A common stock.

21 Nov 2012

Reckitt Benckiser to acquire Schiff

Reckitt Benckiser Group PLC today announces it has signed a definitive merger agreement with Schiff Nutrition International, Inc. a leading provider of branded vitamins, nutrition supplements and nutrition bars in the United States and elsewhere. The Board of Directors of Schiff has approved the transaction and will recommend that its stockholders tender their shares into Reckitt Benckiser's previously announced cash tender offer of $42.00 per share, valuing Schiff at $1.4 billion.

21 Nov 2012

AspenBio Pharma closes underwritten public offering of 1,946,000 shares of common stock

AspenBio Pharma, Inc., an in vitro diagnostic company, today announced the closing of an underwritten public offering of 1,946,000 shares of common stock at an offering price of $2.10 per share.

21 Nov 2012

Concord Medical third quarter 2012 total net revenues increase 65.2% to RMB206.1 million

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang'an Hospital, today reported its unaudited consolidated financial results for the third quarter ended September 30, 2012.

21 Nov 2012

Alpha Imaging announces acquisition of Chesapeake Applications

Alpha Imaging LLC, a leading distributor of advanced medical imaging equipment based in Cleveland, Ohio, today announced they have acquired Chesapeake Applications Inc., a Pennsylvania-based company, to enhance their clinical applications training portfolio.

21 Nov 2012

Patheon to launch $30 million transferable rights offering

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.

19 Nov 2012

CCBC second quarter 2013 revenues increase 30.5% to RMB128.5 million

China Cord Blood Corporation, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2013, which ended September 30, 2012.

19 Nov 2012

Thermo Fisher announces opening of new facility in Suzhou, China

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its new facility in Suzhou, China, for the manufacturing of life sciences consumables and equipment. The facility expands the company's global manufacturing footprint and establishes local production capabilities to meet increased customer demand in China and other Asia-Pacific markets.

From Thermo Fisher Scientific Inc. 16 Nov 2012

Courtagen, AGBL enter exclusive distribution agreement for clinical tests

Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders.

15 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

AspenBio Pharma provides clinical and business update for third quarter 2012

AspenBio Pharma, Inc., an in vitro diagnostic company, today provided a clinical and business update for the third quarter 2012. The Company reported it has started the hospital training phase of its pivotal U.S. clinical study and remains on track to initiate patient enrollment before the end of the year.

13 Nov 2012

Key areas of disease neglected by UK funding for infectious diseases

UK funding for infectious diseases research is neglecting some of the diseases that result in the highest rates of death and disability, according to an Article published Online First in The Lancet Infectious Diseases.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012